VYNE Therapeutics Inc.

Yarrow Bioscience, Inc. (formerly VYNE Therapeutics Inc.) reported a net loss of $(6.51) million for the second quarter of 2026 and $(9.26) million for the first half of 2026. The company, which recently completed a merger with Pre-Merger Yarrow, ended the quarter with $18.67 million in cash and cash equivalents. Yarrow also announced the initiation of a combined Phase 2a/Phase 2b trial for its lead product candidate, YB-101, in patients with Graves' disease.

VYNE Therapeutics Inc. completed its merger with Yarrow Bioscience, Inc. on July 27, 2026, subsequently changing its name to Yarrow Bioscience, Inc. and focusing on Yarrow's clinical-stage biotechnology business. The company also effected a 1-for-50 reverse stock split and declared a $17.3 million special cash dividend. For the six months ended June 30, 2026, the company reported a net loss of $(6.6) million, with cash and cash equivalents at $22.9 million.

VYNE Therapeutics Inc. entered into an exchange agreement on July 29, 2026, with an existing stockholder. Under the agreement, the stockholder exchanged 133,290 shares of common stock for pre-funded warrants to purchase an aggregate of 133,290 shares of common stock at an exercise price of $0.0001 per share. These warrants are immediately exercisable, subject to a beneficial ownership limitation of 9.99%, which can be increased to 19.99% with 61 days' notice. Following the exchange, the company has 2,669,788 shares of common stock outstanding and pre-funded warrants to purchase 25,914,530 shares of common stock outstanding.

Yarrow Bioscience, Inc. (formerly VYNE Therapeutics Inc.) announced the completion of its merger with Pre-Merger Yarrow Bioscience. The combined company, now named Yarrow Bioscience, Inc., will trade on Nasdaq under the ticker symbol "YARW" starting July 28, 2026. This strategic move was supported by approximately $200 million in private financings, extending the company's cash runway into 2028. The company is focused on advancing YB-101, a potential first-in-class anti-TSHR antibody for Graves' disease and thyroid eye disease, with Phase 2a data expected in 2H 2027.

VYNE Therapeutics Inc. announced updates regarding its previously disclosed merger with Yarrow Bioscience, Inc., a special cash dividend, and a reverse stock split. The special cash dividend was distributed on July 23, 2026, with an ex-dividend date of July 24, 2026. A 1-for-50 reverse stock split is expected on July 24, 2026, with post-split trading commencing on July 27, 2026. The closing of the merger with Yarrow is anticipated early in the week of July 27, 2026, subject to Nasdaq approval, after which the combined company will trade as "Yarrow Bioscience, Inc." under the ticker YARW.

VYNE Therapeutics announced a 1-for-50 reverse stock split of its common stock, approved by stockholders and the board, in connection with its proposed merger with Yarrow Bioscience. The company also declared a special cash dividend of $17.3 million, or approximately $0.40242 per share, payable to stockholders of record as of July 22, 2026. Following the merger, the combined company will trade as Yarrow Bioscience, Inc. under the ticker "YARW".

VYNE Therapeutics Inc. announced that Yarrow Bioscience, Inc., with which VYNE is merging, published an investor presentation. The presentation details Yarrow's lead drug candidate, YB-101, an anti-TSHR antibody for Graves' Disease (GD) and Thyroid Eye Disease (TED). The reverse merger is expected to close around July 24, 2026, with the combined entity trading as NASDAQ: YARW. Yarrow has raised $200 million to date, providing a cash runway into 2028, and is initiating a Phase 2 trial for YB-101 in GD.

VYNE Therapeutics Inc. announced a special cash dividend of an estimated $0.38 per share, totaling approximately $16.5 million. This dividend is in connection with the previously announced merger with Yarrow Bioscience, Inc. The dividend will be payable to stockholders and warrant holders of record as of July 22, 2026, with the payment scheduled for July 23, 2026. The payment is contingent upon the closing of the merger, which is expected around July 24, 2026, pending stockholder approval at a special meeting on July 16, 2026.

VYNE Therapeutics Inc. announced a proposed reverse merger with Yarrow Bioscience, Inc., expected to close in Q3 2026, after which the combined entity will trade as YARW on NASDAQ. Yarrow, founded in 2025, is focused on developing novel therapies for thyroid autoimmune diseases, specifically advancing YB-101, a potential first-in-class anti-TSHR antibody for Graves’ Disease (GD) and Thyroid Eye Disease (TED). The company has secured $200 million in funding, including a pre-closing financing, providing a cash runway into 2028, and has received Fast Track Designation for its GD program.

VYNE Therapeutics Inc. announced a proposed merger with Yarrow Bioscience, Inc., a clinical-stage biotechnology company, expected to close in Q3 2026. This follows a strategic review and the termination of clinical trials for its lead product candidates, VYN202 and repibresib, due to a clinical hold and failure to meet primary endpoints, respectively. For Q1 2026, the company reported a net loss of $3.6 million, a significant improvement from $8.6 million in Q1 2025, largely due to reduced R&D expenses as it winds down operations.